MWCL-1 BioVector®华氏巨球蛋白血症细胞系 / Waldenstrom Macroglobulinemia Cell Line

BioVector® MWCL-1 华氏巨球蛋白血症细胞系 / Waldenstrom Macroglobulinemia Cell Line  

产品名称: BioVector® MWCL-1 细胞
中文名称: BioVector® MWCL-1 人华氏巨球蛋白血症细胞系
英文名称: BioVector® MWCL-1 Human Waldenstrom Macroglobulinemia Cell Line
产品类别: 血液肿瘤细胞系
物种来源: 人 (Homo sapiens)
组织来源: 骨髓 -1-5-9
细胞类型: B淋巴细胞、淋巴浆细胞样细胞、浆细胞 -1-5-9
疾病: 华氏巨球蛋白血症 (Waldenstrom macroglobulinemia, WM) / 淋巴浆细胞性淋巴瘤 (Lymphoplasmacytic lymphoma) -1-2-3
患者信息: 73岁男性 -2-9
形态特性: 混合形态，包含小B淋巴细胞和较大的淋巴浆细胞样细胞及浆细胞 -1-5-9
生长特性: 悬浮生长
构建方法: 从一例73岁男性WM患者的骨髓穿刺物中建立，使用含IL-6和IGF-1的IMDM培养基培养，6个月后转入RPMI-1640培养基 -9
免疫表型: CD3⁻, CD19⁺, CD20⁺, CD27⁺, CD38⁺, CD49D⁺, CD138⁺, cIgM⁺, κ⁺ -1-5-9
细胞遗传学: 17p13 (TP53) 单等位基因缺失 -1-5-9

基因突变:

• TP53: 错义突变，第5外显子 V143A (GTG>GCG)，半合子状态 -1-2-4

• MYD88: p.Leu252Pro (c.755T>C) (L265P) 突变，杂合子状态 -2-4
  特性特征:

1. IgM分泌: 无需外部刺激即可持续分泌高水平免疫球蛋白M (IgM) -1-5-9

2. 肿瘤异质性: 包含不同分化阶段的细胞亚群，可模拟原发肿瘤的异质性 -8

3. 肿瘤起始细胞: CD20⁻CD138⁻亚群具有肿瘤起始细胞特性，包括高效的活性氧清除能力、体外集落形成活性和抗凋亡能力 -8

4. 低氧适应性: 低氧培养条件可诱导CD20⁻CD138⁻细胞比例增加 -8

5. CXCR7表达: CD20⁻CD138⁻亚群中CXCR7 mRNA/蛋白表达水平最高，CXCL12-CXCR7信号可能对该亚群有重要影响 -8
   耐药亚系: 已有对伊布替尼 (Ibrutinib) 耐药和对硼替佐米 (Bortezomib) 耐药的亚系建立 -2-3-4
   培养基: BioVector® MWCL-1 细胞专用完全培养基（基础成分为RPMI-1640培养基，添加10%胎牛血清、1mM丙酮酸钠、2mM L-谷氨酰胺、100 U/mL青霉素和100 μg/mL链霉素）-7-9
   培养条件: 气相：95%空气，5%二氧化碳；温度：37°C
   传代方法: 维持细胞密度在2-9 × 10⁵ cells/mL之间，每2-3天传代或更换新鲜培养基
   冻存液: BioVector® 细胞冻存液（推荐配方：90% FBS + 10% DMSO）
   质控载体: BioVector® pUC19 质粒（用于常规克隆和测序）
   宿主菌: BioVector® DH5α 化学感受态细胞
   质量控制: 支原体检测：阴性；无菌检测：阴性；STR分型：已验证；IgM分泌检测：阳性
   储存与运输: 液氮或干冰运输与保存
   生物安全等级: 1
   仅供科研使用

English:
BioVector® MWCL-1 Waldenstrom Macroglobulinemia Cell Line Datasheet

Product Name: BioVector® MWCL-1 Cells
Chinese Name: BioVector® MWCL-1 人华氏巨球蛋白血症细胞系
English Name: BioVector® MWCL-1 Human Waldenstrom Macroglobulinemia Cell Line
Product Category: Hematologic Cancer Cell Line
Species of Origin: Human (Homo sapiens)
Tissue of Origin: Bone marrow -1-5-9
Cell Type: B lymphocytes, lymphoplasmacytic cells, plasma cells -1-5-9
Disease: Waldenstrom macroglobulinemia (WM) / Lymphoplasmacytic lymphoma -1-2-3
Patient Information: 73-year-old male -2-9
Morphology: Mixed morphology, comprising small B lymphocytes and larger lymphoplasmacytic cells and plasma cells -1-5-9
Growth Characteristics: Suspension
Derivation: Established from bone marrow aspirate of a 73-year-old male WM patient, cultured initially in IMDM medium with IL-6 and IGF-1, then transitioned to RPMI-1640 medium after 6 months -9
Immunophenotype: CD3⁻, CD19⁺, CD20⁺, CD27⁺, CD38⁺, CD49D⁺, CD138⁺, cIgM⁺, κ⁺ -1-5-9
Cytogenetics: Monoallelic deletion of 17p13 (TP53) -1-5-9
Gene Mutations:

• TP53: Missense mutation, exon 5 V143A (GTG>GCG), hemizygous -1-2-4

• MYD88: p.Leu252Pro (c.755T>C) (L265P) mutation, heterozygous -2-4
  Characteristics:

1. IgM Secretion: Constitutively secretes high levels of immunoglobulin M (IgM) without external stimulation -1-5-9

2. Tumor Heterogeneity: Contains subpopulations at different differentiation stages, recapitulating the heterogeneity of the primary tumor -8

3. Tumor-Initiating Cells: The CD20⁻CD138⁻ subpopulation exhibits tumor-initiating cell properties, including efficient ROS scavenging, in vitro colony formation, and apoptosis resistance -8

4. Hypoxic Adaptation: Hypoxic culture conditions induce an increase in the CD20⁻CD138⁻ subpopulation -8

5. CXCR7 Expression: The CD20⁻CD138⁻ subpopulation shows highest CXCR7 mRNA/protein expression; CXCL12-CXCR7 signaling may influence this subpopulation -8
   Drug-Resistant Sublines: Ibrutinib-resistant and Bortezomib-resistant sublines have been established -2-3-4
   Culture Medium: BioVector® Complete Medium for MWCL-1 Cells (Composition: RPMI-1640 medium supplemented with 10% fetal bovine serum, 1mM sodium pyruvate, 2mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin) -7-9
   Culture Conditions: Atmosphere: 95% air, 5% CO₂; Temperature: 37°C
   Subculturing Method: Maintain cell density between 2-9 × 10⁵ cells/mL; subculture or replenish with fresh medium every 2-3 days
   Freeze Medium: BioVector® Cell Freeze Medium (Recommended composition: 90% FBS + 10% DMSO)
   Control Vector: BioVector® pUC19 Plasmid (for routine cloning and sequencing)
   Host Strain: BioVector® DH5α Chemically Competent Cells
   Quality Control: Mycoplasma: Negative; Sterility: Negative; STR Profiling: Authenticated; IgM Secretion: Positive
   Storage and Shipment: Stored and shipped in liquid nitrogen or on dry ice
   Biosafety Level: 1
   For Research Use Only

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net